Form 4: Stoke Therapeutics' General Counsel Jonathan Allan Sells Shares
SEC Filing
Jonathan Allan, General Counsel of Stoke Therapeutics, sold shares of common stock on March 28, 2024, according to a Form 4 filing with the SEC.
Summary
- On March 28, 2024, Jonathan Allan, the General Counsel & Corp Sec of Stoke Therapeutics, sold 5,026 shares of common stock at a price of $13.1888 per share.
- An additional 100 shares were sold on the same day at $13.81 per share.
- These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2023.
- Following these transactions, Allan directly owns 2,598 shares of Stoke Therapeutics' common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to insider trading. It doesn't inherently convey positive or negative sentiment, as it simply reports transactions.
Industry Context
This filing is a routine disclosure of insider trading activity. It's common for executives to have pre-arranged trading plans to sell shares over time.
Stakeholder Impact
- The stock sale by a company executive could be perceived negatively by some shareholders, although the existence of a pre-arranged trading plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 2023-12-15 | Date of adoption of Rule 10b5-1 trading plan |
| 2024-03-28 | Date of stock sale transactions |
| 2024-04-01 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.